ReviewThe World Allergy Organization journal2023
Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL.
Review in The World Allergy Organization journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Omalizumab for pediatric allergic asthma: evidence-based insights on efficacy and safety from a meta-analysis of randomized trials.Frontiers in pharmacology · 2026Pooled it
- Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.Current allergy and asthma reports · 2026Review
- Treatment of bronchial asthma - A simplified overview.Lung India : official organ of Indian Chest Society · 2026Article
- A Delphi Consensus on Clinical Features, Diagnosis, and Treatment of Chronic Rhinosinusitis With Nasal Polyps in the ASEAN Region.World journal of otorhinolaryngology - head and neck surgery · 2025Article
- Epigenetic patient stratification reveals a sub-endotype of type 2 asthma with altered B-cell response.medRxiv : the preprint server for health sciences · 2025Article
- Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients.Yonsei medical journal · 2025Article
- Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach.Journal of clinical medicine · 2025Review
- Recombinant BCG Expressing IL-12 as A Novel Immunomodulatory Strategy for Allergic Asthma: Opportunities and Challenges.Clinical reviews in allergy & immunology · 2025Review
- Omalizumab in Food Allergy in Children: Current Evidence and Future Perspectives.Life (Basel, Switzerland) · 2025Review
- Observational
- Treatment of allergic bronchopulmonary aspergillosis with biologics.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Serological markers, pulmonary function, and prognosis in pediatric asthma: predictive model development and validation.American journal of translational research · 2025Article
- Efficacy of Biologic Therapies in the Management of Allergic Rhinitis: A Systematic Review.Cureus · 2024Review
- Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model.Life (Basel, Switzerland) · 2024Review
- Treatment patterns and factors associated with discontinuation of monoclonal antibodies.SAGE open medicine · 2024Article
- Case report: Advanced age at transplantation and pre-emptive treatment with dupilumab in DOCK8 deficiency.Frontiers in immunology · 2024Article
- Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study.BMC pulmonary medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin E (IgE) plays a critical role in the allergen-initiated inflammatory pathway and thus serves as a viable therapeutic target in allergic or IgE-mediated diseases such as asthma. Omalizumab, an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.